Alpha TAVR System

About Laguna Tech

Laguna Tech is an early-stage, pre-revenue medical device company targeting a significant unmet need in structural heart disease: the treatment of pure or predominant Aortic Regurgitation (AR) with a transcatheter solution. Its core innovation, the ZETA valve, is a hybrid device combining features of balloon-expandable and self-expanding technologies to securely anchor in non-calcified anatomy, a key challenge in AR. The company has initiated first-in-human (FIH) clinical trials, reporting six successful initial cases, and is positioning itself to capture a share of the multi-billion dollar TAVR market by addressing a patient population with no currently approved transcatheter devices in the US.

Therapeutic Areas

Other Aortic Stenosis (AS) Drugs